TRCT
ALZN icon

Tower Research Capital (TRC)’s Alzamend Neuro ALZN Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.55K Buy
6,184
+4,103
+197% +$8.2K ﹤0.01% 4050
2025
Q4 		$3.79K Buy
2,081
+475
+30% +$1.08K ﹤0.01% 4313
2025
Q3 		$3.82K Buy
1,606
+809
+102% +$2.1K ﹤0.01% 4444
2025
Q2 		$2.32K Buy
+797
New +$3.95K ﹤0.01% 4667
2025
Q1 		– Sell
-43
Closed -$450 – 5153
2024
Q4 		$450 Sell
43
-420
-91% -$5.4K ﹤0.01% 5267
2024
Q3 		$7.04K Buy
463
+405
+698% +$10.6K ﹤0.01% 4083
2024
Q2 		$2.04K Buy
58
+5
+9% +$286 ﹤0.01% 5061
2024
Q1 		$4.75K Buy
53
+16
+43% +$1.37K ﹤0.01% 4637
2023
Q4 		$2.95K Buy
37
+1
+3% +$164 ﹤0.01% 5147
2023
Q3 		$11.5K Buy
36
+23
+177% +$11K ﹤0.01% 3985
2023
Q2 		$8.78K Sell
13
-9
-41% -$7.05K ﹤0.01% 4373
2023
Q1 		$12K Buy
22
+9
+69% +$6.77K ﹤0.01% 4044
2022
Q4 		$10K Buy
+13
New +$18.8K ﹤0.01% 3946
2022
Q3 		– Sell
-11
Closed -$13K – 6027
2022
Q2 		$13K Buy
11
+2
+22% +$2.59K ﹤0.01% 4192
2022
Q1 		$15K Buy
+9
New +$16.9K ﹤0.01% 3790
2021
Q4 		– Sell
-20
Closed -$82K – 6105
2021
Q3 		$82K Buy
20
+18
+900% +$98.9K ﹤0.01% 2562
2021
Q2 		$18K Buy
+2
New +$25.8K ﹤0.01% 3977

Other funds holding ALZN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Tower Research Capital (TRC)'s ALZN Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Alzamend Neuro (ALZN) stake by 197% in Q1 2026, buying an estimated $8.2K and bringing the position to 6,184 shares worth $6.55K. The position accounts for ﹤0.01% of the portfolio, ranked #4050.

Tower Research Capital (TRC) first reported a position in ALZN in Q2 2021 and has held it in 17 quarters since. The position peaked at $82K in Q3 2021. 12 funds tracked by Wall St. Rank hold ALZN as of Q1 2026.

  • Tower Research Capital (TRC) held 6,184 shares of Alzamend Neuro worth $6.55K as of Q1 2026.
  • Tower Research Capital (TRC) bought 4,103 Alzamend Neuro shares in Q1 2026, an estimated $8.2K.
  • Alzamend Neuro made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4050 holding.
  • Tower Research Capital (TRC) first reported a position in Alzamend Neuro in Q2 2021 and has held it in 17 quarters since.
  • Tower Research Capital (TRC)'s Alzamend Neuro position peaked at $82K in Q3 2021.
  • 12 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.